|
1
|
Tan EM, Cohen AS, Fries JF, Masi AT,
McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ:
The 1982 revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum. 25:1271–1277. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hochberg MC: Updating the American College
of Rheumatology revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsang-A-Sioje MW and Bultink IE: Systemic
lupus erythematosus: Review of synthetic drugs. Expert Opin
Pharmacother. 16:2793–2806. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chan RW, Lai FM, Li EK, Tam LS, Chow KM,
Li PK and Szeto CC: The effect of immunosuppressive therapy on the
messenger RNA expression of target genes in the urinary sediment of
patients with active lupus nephritis. Nephrol Dial Transplant.
21:1534–1540. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alarcón GS, Calvo-Alén J, McGwin G Jr,
Uribe AG, Toloza SM, Roseman JM, Fernández M, Fessler BJ, Vilá LM,
Ahn C, et al: Systemic lupus erythematosus in a multiethnic cohort:
LUMINA XXXV. Predictive factors of high disease activity over time.
Ann Rheum Dis. 65:1168–1174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Griffiths B, Mosca M and Gordon C:
Assessment of patients with systemic lupus erythematosus and the
use of lupus disease activity indices. Best Pract Res Clin
Rheumatol. 19:685–708. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lisnevskaia L, Murphy G and Isenberg D:
Systemic lupus erythematosus. Lancet. 384:1878–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weening JJ, D'Agati VD, Schwartz MM,
Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T,
Ferrario F, et al: The classification of glomerulonephritis in
systemic lupus erythematosus revisited. Kidney Int. 65:521–530.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Austin HA III, Muenz LR, Joyce KM,
Antonovych TT and Balow JE: Diffuse proliferative LN:
Identification of specific pathologic features affecting renal
outcome. Kidney Int. 25:689–695. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Descombes E, Droz D, Drouet L, Grünfeld JP
and Lesavre P: Renal vascular lesions in lupus nephritis. Medicine
(Baltimore). 76:355–368. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Parikh SV, Nagaraja HN, Hebert L and Rovin
BH: Renal flare as a predictor of incident and progressive CKD in
patients with lupus nephritis. Clin J Am Soc Nephrol. 9:279–284.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hahn BH, McMahon MA, Wilkinson A, Wallace
WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ,
Yazdany J, et al: American College of Rheumatology guidelines for
screening, treatment, and management of lupus nephritis. Arthritis
Care Res (Hoboken). 64:797–808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Illei GG, Takada K, Parkin D, Austin HA,
Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, et
al: Renal flares is common in patients with severe proliferative
lupus nephritis treated with pulse immunosuppressive therapy:
Long-term followup of a cohort of 145 patients participating in
randomized controlled studies. Arthritis Rheum. 46:995–1002. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gibson KL, Gipson DS, Massengill SA,
Dooley MA, Primack WA, Ferris MA and Hogan SL: Predictors of
relapse and end stage kidney disease in proliferative lupus
nephritis: Focus on children, adolescents, and young adults. Clin J
Am Soc Nephrol. 12:1962–1967. 2009. View Article : Google Scholar
|
|
15
|
Contreras G, Tozman E, Nahar N and Metz D:
Maintenance therapies for proliferative lupus nephritis:
Mycophenolate mofetil, azathioprine and intravenous
cyclophosphamide. Lupus. 14 Suppl 1:S33–S38. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moon SJ, Park HS, Kwok SK, Ju J, Choi BS,
Park KS, Min JK, Kim HY and Park SH: Predictors of renal relapse in
Korean patients with lupus nephritis who achieved remission six
months following induction therapy. Lupus. 22:527–537. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Imran TF, Yick F, Verma S, Estiverne C,
Ogbonnaya-Odor C, Thiruvarudsothy S, Reddi AS and Kothari N: Lupus
nephritis: An update. Clin Exp Nephrol. 20:1–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan N, Amigues I, Lyman S, Duculan R, Aziz
F, Crow MK and Kirou KA: A surge in anti-dsDNA titer predicts a
severe lupus flare within six months. Lupus. 23:293–298. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borg Ter EJ, Horst G, Hummel EJ, Limburg
PC and Kallenberg CG: Measurement of increases in
anti-double-stranded DNA antibody levels as a predictor of disease
exacerbation in systemic lupus erythematosus: A long-term,
prospective study. Arthritis Rheum. 33:634–643. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coremans IE, Spronk PE, Bootsma H, Daha
MR, van der Voort EA, Kater L, Breedveld FC and Kallenberg CG:
Changes in antibodies to C1q predict renal relapses in systemic
lupus erythematosus. Am J Kidney Dis. 26:595–601. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valões CC, Molinari BC, Pitta AC,
Gormezano NW, Farhat SC, Kozu K, Sallum AM, Appenzeller S, Sakamoto
AP, Terreri MT, et al: Anti-ribosomal P antibody: A multicenter
study in childhood-onset systemic lupus erythematosus patients.
Lupus. 26:484–489. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Keith MP, Moratz C and Tsokos GC: Anti-RNP
immunity: Implications for tissue injury and the pathogenesis of
connective tissue disease. Autoimmunity Rev. 6:232–236. 2007.
View Article : Google Scholar
|
|
23
|
Lu R, Robertson JM, Bruner BF, Guthridge
JM, Neas BR, Nath SK, Kelly JA, Sivils Moser KL, Chakravarty EF,
Kamen DL, et al: Multiple autoantibodies display association with
lymphopenia, proteinuria, and cellular casts in a large, ethnically
diverse SLE patient cohort. Autoimmune Dis.
2012:8196342012.PubMed/NCBI
|
|
24
|
Grootscholten C, Ligtenberg G, Hagen EC,
van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn
JA, Weening JJ, van Houwelingen HC, et al:
Azathioprine/methylprednisolone versus cyclophosphamide in
proliferative lupus nephritis. Kidney Int. 70:732–742. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan TM, Tse KC, Tang CS, Mok MY and Li
FK: Hong Kong Nephrology Study Group: Long-term study of
mycophenolate mofetil as continuous induction and maintenance
treatment for diffuse proliferative lupus nephritis. J Am Soc
Nephrol. 16:1076–1084. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dooley MA, Jayne D, Ginzler EM, Isenberg
D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, et
al: Mycophenolate versus azathioprine as maintenance therapy for
lupus nephritis. N Engl J Med. 365:1886–1895. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yap DY, Ma MK, Mok MM, Tang CS and Chan
TM: Long-term data on corticosteroids and mycophenolate mofetil
treatment in lupus nephritis. Rheumatology (Oxford). 52:480–486.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yap DY and Chan TM: Lupus nephritis in
asia: Clinical features and management. Kidney Dis (Basel).
2:100–109. 2015. View Article : Google Scholar
|
|
29
|
Ponticelli C and Moroni G:
Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert
Opin Drug Saf. 3:411–419. 2017. View Article : Google Scholar
|
|
30
|
Bertsias GK, Tektonidou M, Amoura Z,
Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T,
Doria A, et al: Joint European League Against Rheumatism and
European Renal Association-European Dialysis and Transplant
Association (EULAR/ERA-EDTA) recommendations for the management of
adult and paediatric lupus nephritis. Ann Rheum Dis. 71:1771–1782.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boumpas DT, Austin HA III, Vaughn EM,
Klippel JH, Steinberg AD, Yarboro CH and Balow JE: Controlled trial
of pulse methylprednisolone versus two regimens of pulse
cyclophosphamide in severe lupus nephritis. Lancet. 340:741–745.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen Y, Sun J, Zou K, Yang Y and Liu G:
Treatment for lupus nephritis: An overview of systematic reviews
and meta-analyses. Rheumatol Int. 7:1089–1099. 2017. View Article : Google Scholar
|
|
33
|
Rovin BH and Parikh SV: Lupus nephritis:
The evolving role of novel therapeutics. Am J Kidney Dis.
63:677–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
